<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481256</url>
  </required_header>
  <id_info>
    <org_study_id>73750</org_study_id>
    <nct_id>NCT04481256</nct_id>
  </id_info>
  <brief_title>TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY</brief_title>
  <acronym>TAPESTRY</acronym>
  <official_title>TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Verbeeten Insituut Tilburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiotherapeutic Institute Friesland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Centrum Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiotherapy Group Deventer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deventer Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zuyderland Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZGT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the feasibility of treatment with bintrafusp
      alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in
      patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and
      radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on
      days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1,
      22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose
      of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the
      first cycle of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa</measure>
    <time_frame>36 months</time_frame>
    <description>The primary outcome of this study is the percentage of patients that completes at least two cycles of bintrafusp alfa together with their chemoradiotherapy regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of toxicity</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence and severity of toxicity defined according to CTCAE v5 and and Radiation Oncology Group (RTOG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage completion</measure>
    <time_frame>36 months</time_frame>
    <description>Percentage completion of chemotherapy and radiation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage withdrawal rate</measure>
    <time_frame>36 months</time_frame>
    <description>Percentage withdrawal rate from chemoradiation due to bintrafusp alfa related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional progression</measure>
    <time_frame>36 months</time_frame>
    <description>Infield locoregional progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression</measure>
    <time_frame>36 months</time_frame>
    <description>Any progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ C30))</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Quality of life ranging from 0-100 with 100 being best Quality of Life with special focus on dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>To determine the number and grade of adverse events of bintrafusp alfa combined with chemoradiotherapy according to NCI common toxicity criteria (CTC) version 5</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker</measure>
    <time_frame>54 months</time_frame>
    <description>To perform exploratory biomarker analyses for treatment response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiotherapy</intervention_name>
    <description>External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.</description>
    <arm_group_label>1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinoma of the esophagus or gastro esophageal
             junction.

          -  Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra
             Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients
             with M1 disease solely on the basis of supraclavicular metastasis are eligible.
             Patients with resectable tumors refusing radical surgery are eligible.

          -  Locoregional recurrences without distant metastasis after surgery alone or
             endoscopical resection

          -  Locoregional recurrences without distant metastasis after neoadjuvant chemoradiation +
             resection or definitive chemoradiation outside the previously irradiated area,
             provided that full dose of radiation can safely be delivered.

          -  Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible
             if all other criteria are fulfilled.

          -  If the tumor extends below the gastroesophageal (GE) junction into the proximal
             stomach, the bulk of the tumor must involve the esophagus or GE junction.

          -  Age ≥ 18.

          -  ECOG performance status 0-2 (cf. Appendix A).

          -  Adequate hematological, renal and hepatic functions defined as:

               -  Neutrophils ≥ 1.5 x 109/L

               -  Platelets ≥ 100 x 109/L

               -  Hemoglobin ≥ 5.6 mmol

               -  Total bilirubin ≤ 1.5 x upper normal limit

               -  ASAT and ALAT ≤ 1.5 x upper normal limit, Alkaline Phosphatase ≤ 2.5 x upper
                  normal limit.

               -  PT (INR) ≤ 1.5 x upper normal limit and aPTT ≤ 1.5 x upper normal limit.

               -  Creatinine clearance (Cockroft) &gt; 60 ml/min

          -  Written, voluntary informed consent

          -  Patients must be accessible to management and follow-up in the treatment center

        Exclusion Criteria:

          -  Past or current history of malignancy other than entry diagnosis interfering with
             prognosis of esophageal cancer.

          -  Patient with tracheo-esophageal fistula or extension into the mucosal layer of the
             trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is
             allowed, but not through the trachea.

          -  Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus
             level.

          -  Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.

          -  Patient (male or female) in the reproductive age is not willing to use highly
             effective methods of contraception (per institutional standard) during treatment and
             for 6 months (male or female) after the end of treatment.

          -  Previous chemotherapy, radiation and/or treatment with checkpoint inhibitors for the
             currently present esophageal tumor.

          -  Previous chemotherapy and/or treatment with targeted agents and/or checkpoint
             inhibitors for other forms of cancer within the last six months.

          -  Previous radiation to the mediastinum precluding full dose radiation of the currently
             present esophageal tumor.

          -  Persisting grade &gt;1 NCI CTCAE 5.0 toxicity (except alopecia and vitiligo) related to
             prior therapy; however, grade ≤2 sensory neuropathy is acceptable.

          -  Presence of an esophageal stent.

          -  History of bleeding diathesis or major bleeding event (grade ≥ 2) in the month prior
             to first dose of trial treatment.

          -  Clinically significant cardiovascular disease precluding safe treatment with
             chemoradiation.

          -  Evidence of pulmonary fibrosis and/or clinically significant impairment of lung
             function precluding safe treatment with chemoradiation. In case of doubt about
             pulmonary function, a lung function test should be performed and, in case of
             abnormalities, discussed with the principle investigator.

          -  Serious underlying medical condition which would impair the ability of the patient to
             receive the planned treatment, including prior allergic reactions to drugs containing
             cremophor, such as teniposide or cyclosporine.

          -  Mental status that would prohibit the understanding and giving of informed consent.

          -  Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or
             tube feeding.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs). Replacement therapy (e.g., thyroxine for patients with a history of
             autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus,
             or physiologic corticosteroid replacement therapy for adrenal or pituitary
             insufficiency, etc.) is not considered a form of systemic treatment. Patients with
             vitiligo with dermatological manifestations only are eligible to enter the study.

          -  A diagnosis of immunodeficiency or is receiving systemic steroid therapy (&gt;10 mg/day
             prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days
             prior to the first dose of trial treatment.

          -  Diagnosis of HIV unless stable on antiretroviral therapy for at least 4 weeks, no
             evidence of multi-drug resistance, viral load of &lt; 400 copies/ml and CD4+ T-cells ≥
             350 cells/µl.

          -  Active HBV/HCV. Participants on a stable dose of antiviral therapy with HBV/HCV viral
             load below the limit of quantification are eligible.

          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis.

          -  An active infection requiring systemic therapy, which has not resolved 3 days (simple
             infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior
             to the first dose of trial treatment.

          -  Administration of a live vaccine within 30 days prior to the first dose of trial
             treatment. Seasonal flu vaccines that do not contain a live virus are permitted.

          -  Patients with prior allogeneic stem cell or solid organ transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linde Veen</last_name>
    <phone>020-5665955</phone>
    <email>l.veen1@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanneke WM van Laarhoven, MD, PhD</last_name>
    <phone>020-5665955</phone>
    <email>h.vanlaarhoven@amsterdamumc.nl</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>H.W.M. van Laarhoven</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Definitive chemoradiation</keyword>
  <keyword>TGF-beta inhibition</keyword>
  <keyword>PDL-1 ihibition</keyword>
  <keyword>feasability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

